[go: up one dir, main page]

GB2578008B - 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment - Google Patents

1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Download PDF

Info

Publication number
GB2578008B
GB2578008B GB1916084.5A GB201916084A GB2578008B GB 2578008 B GB2578008 B GB 2578008B GB 201916084 A GB201916084 A GB 201916084A GB 2578008 B GB2578008 B GB 2578008B
Authority
GB
United Kingdom
Prior art keywords
pyrrolin
acetyl
nitro
phenyl
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1916084.5A
Other versions
GB201916084D0 (en
GB2578008A (en
Inventor
Kuznecovs Jevgenijs
Veinbergs Grigorijs
Vorona Maksims
Domraceva Ilona
Kanepe-Lapsa Iveta
Leonciks Ainars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB201916084D0 publication Critical patent/GB201916084D0/en
Publication of GB2578008A publication Critical patent/GB2578008A/en
Application granted granted Critical
Publication of GB2578008B publication Critical patent/GB2578008B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1916084.5A 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Active GB2578008B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-17-51A LV15384B (en) 2017-07-24 2017-07-24 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in the treatment of cancer
PCT/IB2018/051917 WO2019021067A1 (en) 2017-07-24 2018-03-22 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in cancer treatment

Publications (3)

Publication Number Publication Date
GB201916084D0 GB201916084D0 (en) 2019-12-18
GB2578008A GB2578008A (en) 2020-04-15
GB2578008B true GB2578008B (en) 2022-03-16

Family

ID=59858757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1916084.5A Active GB2578008B (en) 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment

Country Status (3)

Country Link
GB (1) GB2578008B (en)
LV (1) LV15384B (en)
WO (1) WO2019021067A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
JP2002504916A (en) 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Barbituric acid derivatives with antimetastatic and antitumor activity
WO2006008303A1 (en) 2004-07-21 2006-01-26 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof
KR100829257B1 (en) 2006-06-22 2008-05-14 부경대학교 산학협력단 Carboxylic Glucosamine Compounds Inhibiting the Expression and Activity of Matrix Metalloproteinase-9 in Human Fibrosarcoma Cells and Matrix Metalloproteinase-9 Inhibitors Containing it

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG X C ET AL, "Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 10, doi:10.1016/J.EJMECH.2007.12.020, ISSN 0223-5234, (20081001), Abstract, introduction; table 1 *

Also Published As

Publication number Publication date
GB201916084D0 (en) 2019-12-18
GB2578008A (en) 2020-04-15
LV15384A (en) 2019-02-20
WO2019021067A1 (en) 2019-01-31
LV15384B (en) 2019-05-20

Similar Documents

Publication Publication Date Title
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
IL251630A0 (en) Combination therapy for use in cancer therapy
IL276733A (en) Use of eribulin in the treatment of cancer
PT3576740T (en) Cancer treatment
IL251905A0 (en) Apilimod for use in the treatment of renal cancer
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer
IL274626A (en) Cancer treatment
IL262143A (en) Improvements in cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL260814A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
IL268265B (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
GB201713852D0 (en) Cancer treatment
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer